JP4065554B2 - 抗体の調製 - Google Patents

抗体の調製 Download PDF

Info

Publication number
JP4065554B2
JP4065554B2 JP51633993A JP51633993A JP4065554B2 JP 4065554 B2 JP4065554 B2 JP 4065554B2 JP 51633993 A JP51633993 A JP 51633993A JP 51633993 A JP51633993 A JP 51633993A JP 4065554 B2 JP4065554 B2 JP 4065554B2
Authority
JP
Japan
Prior art keywords
ser
gly
thr
antibody
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP51633993A
Other languages
English (en)
Japanese (ja)
Other versions
JPH07500017A (ja
Inventor
ボルト，サラ・ルイーズ
クラーク，マイケル・ロナルド
ゴーマン，スコット・デヴィッド
ルートリッジ，エドワード・グラハム
ウォルドマン，ハーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of JPH07500017A publication Critical patent/JPH07500017A/ja
Application granted granted Critical
Publication of JP4065554B2 publication Critical patent/JP4065554B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP51633993A 1992-03-24 1992-10-21 抗体の調製 Expired - Lifetime JP4065554B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929206422A GB9206422D0 (en) 1992-03-24 1992-03-24 Antibody preparation
GB9206422.9 1992-03-24
PCT/GB1992/001933 WO1993019196A1 (en) 1992-03-24 1992-10-21 ANTI-CD3 AGLYCOSYLATED IgG ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003270135A Division JP4113467B2 (ja) 1992-03-24 2003-07-01 抗体の調製

Publications (2)

Publication Number Publication Date
JPH07500017A JPH07500017A (ja) 1995-01-05
JP4065554B2 true JP4065554B2 (ja) 2008-03-26

Family

ID=10712757

Family Applications (3)

Application Number Title Priority Date Filing Date
JP51633993A Expired - Lifetime JP4065554B2 (ja) 1992-03-24 1992-10-21 抗体の調製
JP2003270135A Expired - Fee Related JP4113467B2 (ja) 1992-03-24 2003-07-01 抗体の調製
JP2005351160A Expired - Fee Related JP4113890B2 (ja) 1992-03-24 2005-12-05 抗体の調製

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2003270135A Expired - Fee Related JP4113467B2 (ja) 1992-03-24 2003-07-01 抗体の調製
JP2005351160A Expired - Fee Related JP4113890B2 (ja) 1992-03-24 2005-12-05 抗体の調製

Country Status (12)

Country Link
US (11) US5585097A (OSRAM)
EP (1) EP0586617B1 (OSRAM)
JP (3) JP4065554B2 (OSRAM)
KR (1) KR100238497B1 (OSRAM)
AT (1) ATE155818T1 (OSRAM)
AU (1) AU671085B2 (OSRAM)
CA (1) CA2109815C (OSRAM)
DE (1) DE69221147T2 (OSRAM)
ES (1) ES2106195T3 (OSRAM)
GB (1) GB9206422D0 (OSRAM)
GR (1) GR3024489T3 (OSRAM)
WO (1) WO1993019196A1 (OSRAM)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO1997046589A2 (en) * 1996-06-07 1997-12-11 Neorx Corporation Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
NZ539776A (en) * 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
JP2003514552A (ja) * 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
JP4309656B2 (ja) * 2000-12-14 2009-08-05 ジェネンテック・インコーポレーテッド 原核生物で生成させた抗体とその用途
US6720165B2 (en) * 2001-06-14 2004-04-13 Zyomix, Inc. Methods for making antibody fragments and compositions resulting therefrom
KR100968664B1 (ko) * 2001-08-27 2010-07-06 제넨테크, 인크. 항체 발현 및 조립을 위한 시스템
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
BR0213761A (pt) * 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
US20050129691A1 (en) * 2002-04-25 2005-06-16 Eli Lily And Company Patent Division Method for treating anxiety and mood disorders in older subjects
NZ538996A (en) * 2002-10-31 2008-04-30 Genentech Inc Methods and compositions for increasing antibody production
ATE482235T1 (de) * 2003-06-13 2010-10-15 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004273791A1 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
ES2378167T3 (es) 2003-11-13 2012-04-09 Hanmi Holdings Co., Ltd Complejo de proteína que utiliza fragmento de inmunoglobulina y el método para su preparación
EP1699822B1 (en) 2003-12-30 2008-04-23 MERCK PATENT GmbH Il-7 fusion proteins with antibody portions, their preparation and their use
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
JP5102028B2 (ja) 2004-07-26 2012-12-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｃｄ１５４抗体
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
NZ556788A (en) 2005-01-05 2011-03-31 Biogen Idec Inc Humanized CRIPTO binding molecules with CDRs from murine B3F6
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
WO2006138739A2 (en) * 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
CA2614640A1 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
ES2456672T3 (es) * 2005-08-16 2014-04-23 Hanmi Science Co., Ltd. Un procedimiento para la producción en masa de una región Fc de inmunoglobulina con residuos de metionina iniciales eliminados
WO2007033230A2 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-cd3 antibody formulations
AU2006332138B2 (en) * 2005-12-30 2012-03-22 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
AU2006332155B2 (en) * 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
EP2023955A4 (en) 2006-06-06 2009-10-28 Tolerrx Inc Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
SG10201504662WA (en) * 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
AU2007345745C1 (en) * 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
US20100325744A1 (en) * 2007-05-31 2010-12-23 Genmab A/S Non-glycosylated recombinant monovalent antibodies
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN103052649B (zh) 2010-07-29 2015-12-16 Xencor公司 具有修改的等电点的抗体
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
EP4303237A3 (en) 2010-11-30 2024-03-27 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
WO2012122528A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
MY163539A (en) 2011-03-29 2017-09-15 Roche Glycart Ag Antibody fc variants
ES2732213T3 (es) 2011-05-21 2019-11-21 Macrogenics Inc Moléculas que se unen a CD3 capaces de unirse a CD3 humano y no humano
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
KR102168733B1 (ko) 2011-10-31 2020-10-23 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
EP3495387B1 (en) 2012-07-13 2021-09-01 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014028939A2 (en) 2012-08-17 2014-02-20 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
EP3718556A3 (en) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
WO2014093855A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
EP2943511B1 (en) 2013-01-14 2019-08-07 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP2016093104A (ja) * 2013-02-19 2016-05-26 国立大学法人京都大学 抗ヒトＣＤ３ε抗体又はそのフラグメント、及びそれを有効成分とする免疫抑制剤
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
KR101895634B1 (ko) 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
EP3024851B1 (en) 2013-07-25 2018-05-09 CytomX Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
AP2016009475A0 (en) 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
CN118440206A (zh) 2014-04-07 2024-08-06 中外制药株式会社 免疫活化抗原结合分子
WO2015160928A2 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
CN106459954A (zh) 2014-05-13 2017-02-22 中外制药株式会社 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
PH12016502345B1 (en) 2014-05-28 2023-03-01 Agenus Inc Anti-gitr antibodies and methods of use thereof
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10889653B2 (en) 2014-11-26 2021-01-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
JP6867955B2 (ja) 2015-05-07 2021-05-12 アジェナス インコーポレイテッド 抗ｏｘ４０抗体及びその使用方法
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
CA2993432A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
GB201520191D0 (en) 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
MA44312A (fr) 2015-12-02 2018-10-10 Agenus Inc Anticorps et leurs méthodes d'utilisation
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
KR102366813B1 (ko) 2016-05-27 2022-02-24 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
MX2018016404A (es) 2016-06-21 2019-10-15 Teneobio Inc Anticuerpos de union a cd3.
AU2017290086A1 (en) 2016-06-28 2019-01-24 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP4050034B1 (en) 2016-09-14 2024-05-08 TeneoOne, Inc. Cd3 binding antibodies
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
CA3040504A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
EP3551050A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP4289484A3 (en) 2016-12-07 2024-03-06 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
MA50956A (fr) 2017-04-13 2020-10-14 Agenus Inc Anticorps anti-cd137 et procédés d'utilisation correspondants
HUE062927T2 (hu) 2017-05-01 2023-12-28 Agenus Inc Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
EP4327819A3 (en) 2017-06-30 2024-05-29 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
JP2020529832A (ja) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
TN2020000015A1 (en) 2017-08-03 2021-10-04 Amgen Inc Interleukin-21 muteins and methods of treatment
MX2020002076A (es) 2017-08-25 2020-03-24 Five Prime Therapeutics Inc Anticuerpos de b7-h4 y metodos para usarlos.
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
MX2020006715A (es) 2017-12-27 2020-08-20 Teneobio Inc Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
CN111727197A (zh) 2018-01-12 2020-09-29 美国安进公司 抗pd-1抗体和治疗方法
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
AU2019226011B2 (en) 2018-02-21 2025-11-27 Five Prime Therapeutics, Inc. B7-H4 antibody formulations
MX2020009037A (es) 2018-03-02 2021-01-08 Five Prime Therapeutics Inc Anticuerpos de b7-h4 y métodos para usarlos.
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3781599A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019231326A1 (en) 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20210284732A1 (en) 2018-07-31 2021-09-16 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
US11692031B2 (en) 2018-08-03 2023-07-04 Amgen Research (Munich) Gmbh Antibody constructs for CLDN18.2 and CD3
BR112021005669A2 (pt) 2018-09-28 2021-06-22 Amgen Inc. anticorpos contra bcma solúvel
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
NL2021789B1 (en) 2018-10-10 2020-05-14 Academisch Ziekenhuis Leiden Binding proteins specific for HA-1H and uses thereof
KR20210087472A (ko) 2018-11-01 2021-07-12 산동 뉴 타임 파마슈티칼 코., 리미티드. 이중 특이성 항체 및 그 용도
IL312059A (en) 2018-11-19 2024-06-01 Biora Therapeutics Inc Methods and devices for treating a disease with biotherapeutics
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
EP3947470A1 (en) 2019-04-05 2022-02-09 TeneoBio, Inc. Heavy chain antibodies binding to psma
JP7684656B2 (ja) 2019-06-11 2025-05-28 小野薬品工業株式会社 免疫抑制剤
EA202290054A1 (ru) 2019-06-14 2022-03-25 Тенеобио, Инк. Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
WO2021030488A1 (en) 2019-08-12 2021-02-18 Bienvenue David Leonard 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
HUE068401T2 (hu) 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
IL296537A (en) 2020-03-26 2022-11-01 Univ Vanderbilt Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20230203161A1 (en) 2020-04-29 2023-06-29 Teneobio, Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
US20230174645A1 (en) 2020-05-13 2023-06-08 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
PE20231376A1 (es) 2020-05-17 2023-09-07 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
IL300376A (en) 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
TW202221025A (zh) 2020-08-10 2022-06-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９的ｓａｒｓ—ｃｏｖ—２抗體
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
NL2026614B1 (en) 2020-10-02 2022-06-03 Academisch Ziekenhuis Leiden T cell receptors directed against bob1 and uses thereof
EP4240770A1 (en) 2020-11-06 2023-09-13 Amgen Research (Munich) GmbH Polypeptide constructs selectively binding to cldn6 and cd3
AU2021373318A1 (en) 2020-11-06 2023-05-25 Amgen Inc. Antigen binding domain with reduced clipping rate
TW202233682A (zh) 2020-11-10 2022-09-01 美商安進公司 用於投與ＢＣＭＡｘＣＤ３結合分子之方法
WO2022119976A1 (en) 2020-12-01 2022-06-09 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
MX2023007881A (es) 2020-12-31 2023-07-10 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de los mismos para el tratamiento de la distrofia miotonica.
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
TW202304508A (zh) 2021-03-31 2023-02-01 美商百歐維拉提夫美國公司 減少冷凝集素疾病患者之手術相關溶血
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
WO2023056362A1 (en) 2021-09-30 2023-04-06 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
US20240417458A1 (en) 2021-11-17 2024-12-19 Disc Medicine, Inc. Methods for treating anemia of kidney disease
NL2030990B1 (en) 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
NL2031118B1 (en) 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
JP2025514858A (ja) 2022-04-29 2025-05-09 アストラゼネカ・ユーケイ・リミテッド ＳＡＲＳ－ＣｏＶ－２抗体、及びその使用方法
KR20250010024A (ko) 2022-05-13 2025-01-20 아카데미슈 지켄후이스 라이덴 (에이치.오.디.엔. 라이즈 유니베르시타이어 메디슈 센트럼) 혈액학적 악성 종양의 치료
NL2032130B1 (en) 2022-06-10 2023-12-18 Academisch Ziekenhuis Leiden T cell receptors directed against melanoma-associated antigen and uses thereof
KR20250024831A (ko) 2022-06-15 2025-02-19 바이오버라티브 유에스에이 인코포레이티드 항-보체 C1s 항체 제형
CN119730882A (zh) 2022-06-24 2025-03-28 美国比奥维拉迪维股份有限公司 用于治疗补体介导的疾病的方法
NL2033510B1 (en) 2022-11-11 2024-05-28 Academisch Ziekenhuis Leiden T cell receptors directed against cancer-associated antigens and uses thereof
WO2024150074A2 (en) 2023-01-13 2024-07-18 Takeda Pharmaceutical Company Limited Coronavirus antibodies and therapeutic uses thereof
AU2024229544A1 (en) 2023-03-02 2025-10-16 Alloy Therapeutics, Inc. Anti-cd22 antibodies and uses thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
NL2034657B1 (en) 2023-04-21 2024-10-28 Academisch Ziekenhuis Leiden RCN1-derived TEIPP neoantigens and uses thereof
NL2034658B1 (en) 2023-04-21 2024-10-28 Academisch Ziekenhuis Leiden TIMP3-derived TEIPP neoantigens and uses thereof
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
TW202517301A (zh) 2023-10-06 2025-05-01 美商思進公司 用ｂ７－ｈ４抗體－藥物結合物治療晚期實體腫瘤之方法
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
NL2036853B1 (en) 2024-01-22 2025-08-01 Academisch Ziekenhuis Leiden Haematopoietic-restricted minor histocompatibility antigens and uses thereof
NL2036854B1 (en) 2024-01-22 2025-08-01 Academisch Ziekenhuis Leiden Haematopoietic-restricted Minor Histocompatibility Antigens and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB2216126B (en) * 1988-02-12 1992-06-03 Medical Res Council Antibodies to the antigen campath-1
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
ATE159982T1 (de) * 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991001752A1 (en) * 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP2711163B2 (ja) * 1990-01-12 1998-02-10 新日本製鐵株式会社 耐ｃｏ▲下２▼腐食性の優れた高耐食性低合金ラインパイプ用鋼の製造法
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5968509A (en) * 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
JPH06503194A (ja) * 1990-11-27 1994-04-07 パラスペクティブス　インコーポレイテッド 交代幾何学におけるオブジェクト画像作成システム
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US20050079184A1 (en) * 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells

Also Published As

Publication number Publication date
DE69221147T2 (de) 1998-01-15
DE69221147D1 (de) 1997-09-04
JP2006089501A (ja) 2006-04-06
GR3024489T3 (OSRAM) 1997-11-28
JP4113467B2 (ja) 2008-07-09
US20060088526A1 (en) 2006-04-27
AU2766892A (en) 1993-10-21
ATE155818T1 (de) 1997-08-15
JPH07500017A (ja) 1995-01-05
KR100238497B1 (ko) 2000-01-15
JP2004000249A (ja) 2004-01-08
US20040202657A1 (en) 2004-10-14
US20070154477A1 (en) 2007-07-05
US6706265B1 (en) 2004-03-16
GB9206422D0 (en) 1992-05-06
EP0586617B1 (en) 1997-07-23
US5585097A (en) 1996-12-17
WO1993019196A1 (en) 1993-09-30
ES2106195T3 (es) 1997-11-01
US20070134241A1 (en) 2007-06-14
EP0586617A1 (en) 1994-03-16
US20060165691A1 (en) 2006-07-27
CA2109815A1 (en) 1993-09-30
JP4113890B2 (ja) 2008-07-09
US20060165692A1 (en) 2006-07-27
US20070178092A1 (en) 2007-08-02
US20060165693A1 (en) 2006-07-27
CA2109815C (en) 2003-02-04
US20060269547A1 (en) 2006-11-30
AU671085B2 (en) 1996-08-15

Similar Documents

Publication Publication Date Title
JP4065554B2 (ja) 抗体の調製
RU2244720C2 (ru) Антитело igg с аффинностью связывания в отношении антигенного комплекса cd3, рекомбинантные нуклеиновые кислоты, кодирующие легкую и тяжелую цепи антитела, способ получения системы, способ получения антитела, способ лечения пациента
EP0918797B2 (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
US20030108548A1 (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP1803466B1 (en) Treatment of chronic joint inflammation by an aglycosylated anti-CD3 antibody
JP4195453B2 (ja) Ｔ細胞の活性化と増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその用途
Vandevyver et al. Development and functional characterization of a murine/human chimeric antibody with specificity for the human interleukin-2 receptor
JP4808841B2 (ja) Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその使用法
AU778980B2 (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
HK1021822C (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
HK1021822B (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
HK1097874A (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
AU2008203508A1 (en) Humanized immunoglobulin reactive with a4B7 integrin
MXPA99001462A (es) Inmunoglobulina humanizada reactiva con (alfa4beta7) integrina

Legal Events

Date Code Title Description
A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060818

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080107

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110111

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120111

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130111

Year of fee payment: 5

EXPY Cancellation because of completion of term